Rhumbline Advisers Has $241,000 Stock Holdings in OptimizeRx Corp. $OPRX

Rhumbline Advisers boosted its stake in shares of OptimizeRx Corp. (NASDAQ:OPRX) by 10.5% during the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 27,785 shares of the company’s stock after buying an additional 2,636 shares during the period. Rhumbline Advisers’ holdings in OptimizeRx were worth $241,000 as of its most recent filing with the SEC.

Other large investors also recently made changes to their positions in the company. Blair William & Co. IL raised its holdings in shares of OptimizeRx by 4.9% during the first quarter. Blair William & Co. IL now owns 631,031 shares of the company’s stock worth $5,465,000 after acquiring an additional 29,648 shares during the period. Squarepoint Ops LLC raised its stake in shares of OptimizeRx by 298.8% in the 4th quarter. Squarepoint Ops LLC now owns 41,712 shares of the company’s stock valued at $203,000 after purchasing an additional 31,252 shares during the period. Janney Montgomery Scott LLC lifted its holdings in shares of OptimizeRx by 47.1% in the first quarter. Janney Montgomery Scott LLC now owns 124,751 shares of the company’s stock valued at $1,080,000 after purchasing an additional 39,969 shares in the last quarter. Jane Street Group LLC boosted its position in shares of OptimizeRx by 234.7% during the fourth quarter. Jane Street Group LLC now owns 72,454 shares of the company’s stock worth $352,000 after buying an additional 50,808 shares during the period. Finally, Calamos Advisors LLC bought a new position in shares of OptimizeRx during the first quarter worth about $289,000. Institutional investors own 76.47% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have weighed in on OPRX. Roth Capital reaffirmed a “buy” rating on shares of OptimizeRx in a research report on Friday, August 8th. Stifel Nicolaus boosted their price objective on shares of OptimizeRx from $16.00 to $18.00 and gave the stock a “buy” rating in a research report on Friday, August 8th. Zacks Research upgraded shares of OptimizeRx from a “hold” rating to a “strong-buy” rating in a report on Friday, September 5th. Finally, JMP Securities lifted their price target on shares of OptimizeRx from $14.00 to $20.00 and gave the company a “market outperform” rating in a research note on Monday, August 11th. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $11.81.

OptimizeRx Stock Performance

Shares of OPRX opened at $18.34 on Friday. The company has a debt-to-equity ratio of 0.21, a current ratio of 2.57 and a quick ratio of 2.57. The firm has a 50-day moving average of $16.27 and a 200-day moving average of $12.66. The company has a market cap of $340.57 million, a PE ratio of -33.96 and a beta of 1.20. OptimizeRx Corp. has a one year low of $3.78 and a one year high of $19.47.

Insiders Place Their Bets

In other OptimizeRx news, Director Patrick D. Spangler sold 11,120 shares of the company’s stock in a transaction that occurred on Thursday, August 28th. The stock was sold at an average price of $17.49, for a total value of $194,488.80. Following the sale, the director owned 44,215 shares in the company, valued at $773,320.35. This represents a 20.10% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 5.60% of the stock is currently owned by company insiders.

OptimizeRx Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.